Vasomedical to Showcase Products in Brazil at HOSPITALAR 2014
Highlighted products to include introduction of MobiCare Wireless Multi-Parameter Patient Monitoring
WESTBURY, N.Y. – May 6, 2014 –Vasomedical, Inc. (“Vasomedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP systems, the gold standard of ECP therapy, announced today that it will be exhibiting at the Hospitalar Healthcare Fair from May 20-23, 2014 in São Paulo, Brazil.
HOSPITALAR is a multi-sector specialized healthcare fair featuring approximately 1,250 exhibitors from 37 countries. Over the four day span of the event, approximately 90,000 visitors attend. The Fair represents a platform for showcasing products to physicians, hospitals, clinics, government agencies and other healthcare related visitors.
The Company will be exhibiting and demonstrating its EECP Therapy, an innovative, non-invasive treatment for refractory angina and heart failure and BIOX ECG Holter and Ambulatory Blood Pressure Monitoring devices. The Company will also exhibit the newest addition to its Biox line of products, MobiCare wireless multi-parameter patient monitoring devices.
Hospitalar is one of the most important healthcare forums in the growing Latin American market covering Mexico, Central and South America, as well as the Caribbean region. As an example, Brazil, with one of the largest economies in South America, has the highest potential in the healthcare market, a sector estimated to be worth $167 billion USD.
“We are excited to be participating at HOSPITALAR for the third time, presenting our products to such a large global audience of healthcare professionals,” said Larry Liebman, Vice President of Sales & Marketing at Vasomedical.
“This is an excellent opportunity to expose thousands of people to our innovative devices, generating awareness of our technologies and the many clinical and financial benefits our product solutions offer. In addition, this forum helps us showcase Biox’s OEM capabilities and create opportunities to work with other medical device companies who wish to benefit from our expertise and international experience. With the participation of our colleagues from the US and China, we welcome this opportunity to promote both our products and services to Latin America and other international customers.”
The Vasomedical exhibit will be located at booth #O48, at the junction of Aisle O and Aisle M within the Expo Center Norte exhibition center.
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
firstname.lastname@example.org / email@example.com
Samantha Wolf / Andrew Herweg
KCSA Strategic Communications
firstname.lastname@example.org / email@example.com